Keyword search (4,163 papers available)

"Campbell TS" Authored Publications:

Title Authors PubMed ID
1 Rethinking How to Expand the Evidence Base for Health Behavior Change in Cardiovascular Disease Prevention. Bacon SL, Campbell TS, Lavoie KL 32439011
HKAP
2 Hypertension Canada's 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. Rabi DM, McBrien KA, Sapir-Pichhadze R, Nakhla M, Ahmed SB, Dumanski SM, Butalia S, Leung AA, Harris KC, Cloutier L, Zarnke KB, Ruzicka M, Hiremath S, Feldman RD, Tobe SW, Campbell TS, Bacon SL, Nerenberg KA, Dresser GK, Fournier A, Burgess E, Lindsay P, Rabkin SW, Prebtani APH, Grover S, Honos G, Alfonsi JE, Arcand J, Audibert F, Benoit G, Bittman J, Bolli P, Côté AM, Dionne J, Don-Wauchope A, Edwards C, Firoz T, Gabor JY, Gilbert RE, Grégoire JC, Gryn SE, Gupta M, Hannah-Shmouni F, Hegele RA, Herman RJ, H 32389335
HKAP
3 An international Delphi consensus study to define motivational communication in the context of developing a training program for physicians. Dragomir AI, Boucher VG, Bacon SL, Gemme C, Szczepanik G, Corace K, Campbell TS, Vallis MT, Garber G, Rouleau C, Rabi D, Diodati JG, Ghali W, Lavoie KL 32145022
HKAP
4 Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Leung AA, Nerenberg K, Daskalopoulou SS, McBrien K, Zarnke KB, Dasgupta K, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean D, Tobe SW, Ruzicka M, Burns KD, Vallée M, Prasad GV, Lebel M, Feldman RD, Selby P, Pipe A, Schiffrin EL, McFarlane PA, Oh P, Hegele RA, Khara M, Wilson TW, Penner SB, Burgess E, Herman RJ, Bacon SL, Rabkin SW, Gilbert RE, Campbell TS, Grover S, Honos G, Lindsay P, Hill MD, Coutts SB, Gubitz G, Campbell NR, Moe GW, Howlett JG, Boulanger JM, Prebtani A, Laroc 27118291
HKAP
5 Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. Leung AA, Daskalopoulou SS, Dasgupta K, McBrien K, Butalia S, Zarnke KB, Nerenberg K, Harris KC, Nakhla M, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean D, Tran KC, Tobe SW, Ruzicka M, Burns KD, Vallée M, Prasad GVR, Gryn SE, Feldman RD, Selby P, Pipe A, Schiffrin EL, McFarlane PA, Oh P, Hegele RA, Khara M, Wilson TW, Penner SB, Burgess E, Sivapalan P, Herman RJ, Bacon SL, Rabkin SW, Gilbert RE, Campbell TS, Grover S, Honos G, Lindsay P, Hill MD, Coutts SB, Gubitz G, Campbell 28449828
HKAP
6 Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. Nerenberg KA, Zarnke KB, Leung AA, Dasgupta K, Butalia S, McBrien K, Harris KC, Nakhla M, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean D, Padwal RS, Tran KC, Grover S, Rabkin SW, Moe GW, Howlett JG, Lindsay P, Hill MD, Sharma M, Field T, Wein TH, Shoamanesh A, Dresser GK, Hamet P, Herman RJ, Burgess E, Gryn SE, Grégoire JC, Lewanczuk R, Poirier L, Campbell TS, Feldman RD, Lavoie KL, Tsuyuki RT, Honos G, Prebtani APH, Kline G, Schiffrin EL, Don-Wauchope A, Tobe SW, Gilbert RE, 29731013
NA
7 The evaluation of a brief motivational intervention to promote intention to participate in cardiac rehabilitation: A randomized controlled trial. Rouleau CR, King-Shier KM, Tomfohr-Madsen LM, Bacon SL, Aggarwal S, Arena R, Campbell TS 30017536
HKAP
8 Relationship between antidepressant therapy and risk for cardiovascular events in patients with and without cardiovascular disease. Lavoie KL, Paine NJ, Pelletier R, Arsenault A, Diodati JG, Campbell TS, Pilote L, Bacon SL 30247064
HKAP

 

Title:Relationship between antidepressant therapy and risk for cardiovascular events in patients with and without cardiovascular disease.
Authors:Lavoie KL,  Paine NJ,  Pelletier R,  Arsenault A,  Diodati JG,  Campbell TS,  Pilote L,  Bacon SL
Link:https://www.ncbi.nlm.nih.gov/pubmed/30247064?dopt=Abstract
Publication:
Keywords:
PMID:30247064 Category:Health Psychol Date Added:2019-05-31
Dept Affiliation: HKAP
1 Department of Psychology, University of Québec at Montréal.
2 Montreal Behavioural Medicine Centre, Research Center, CIUSSS-NIM, Hôpital du Sacré-Coeur de Montréal.
3 Department of Psychology, University of Calgary.
4 Division of Clinical Epidemiology, McGill University Health Centre.
5 Department of Health, Kinesiology and Applied Physiology, Concordia University.

Description:

Relationship between antidepressant therapy and risk for cardiovascular events in patients with and without cardiovascular disease.

Health Psychol. 2018 Nov;37(11):989-999

Authors: Lavoie KL, Paine NJ, Pelletier R, Arsenault A, Diodati JG, Campbell TS, Pilote L, Bacon SL

Abstract

OBJECTIVE: The American Heart Association has endorsed depression as a cardiac risk factor and recommends screening as part of routine practice. This has been met with controversy due to inconsistencies in the data linking depression treatment to better cardiovascular outcomes. Our objective was to prospectively assess the association between depression treatment (defined as being prescribed antidepressant medication) and major adverse cardiovascular events (MACE) in patients referred for exercise stress tests.

METHOD: Two thousand three hundred eighty-five consecutive patients presenting for myocardial perfusion exercise stress tests underwent a sociodemographic, medical, and psychiatric interview (Primary Care Evaluation of Mental Disorders [PRIME-MD]) and completed the Beck Depression Inventory (BDI). History of cardiovascular disease (CVD) and antidepressant use was self-reported and verified via chart review. Participants followed over an 8.8-year follow up, and information regarding MACE incidence (including cardiac mortality, nonfatal myocardial infarction, revascularization procedures, cerebrovascular events) was obtained from provincial administrative databases.

RESULTS: 8% (n = 190) of the sample were taking antidepressants at baseline, 41% (n = 916) had a history of CVD, and 38.7% (n = 921) had depression according to the PRIME-MD or BDI. Antidepressant treatment was associated with a 30% reduced risk of MACE (Hazard ratio [HR] = 0.697; 95% confidence interval [CI] = [0.504, 0.964]; p = .029). A 46% reduction in risk was associated with antidepressant treatment among those without CVD (HR = 0.542; 95% CI [0.299, 0.981]; p = .043). In depressed patients, a 33% reduction in risk of MACE associated with antidepressant use was seen (adjusted HR = 0.674; 95% CI [0.440, 1.033]; p = .07).

CONCLUSIONS: Antidepressants may be cardio-protective among patients presenting for stress testing independent of risk factors including CVD and depression. Results support treating depression with antidepressants in this population to reduce risk of MACE. (PsycINFO Database Record (c) 2018 APA, all rights reserved).

PMID: 30247064 [PubMed - indexed for MEDLINE]




BookR developed by Sriram Narayanan
for the Concordia University School of Health
Copyright © 2011-2026
Cookie settings
Concordia University